It implies that besides the intratumoral delivery of therapeutic NO/CO/H2S gases and their prodrugs, the tumor-targeted delivery of related iNOS/HO1/CBS inhibitors by nanomedicine approach also holds great promise to improve anticancer efficacy and avoid side effects. This evidence concerns the gene HMOX1 and neoplasm.